Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease.
Identifieur interne : 000188 ( Main/Exploration ); précédent : 000187; suivant : 000189Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease.
Auteurs : Michel Boutin ; Ying Sun [États-Unis] ; John J. Shacka [États-Unis] ; Christiane Auray-BlaisSource :
- Analytical chemistry [ 1520-6882 ] ; 2016.
English descriptors
- KwdEn :
- Animals, Brain (metabolism), Chromatography, High Pressure Liquid, Disease Models, Animal, Galactosylceramides (analysis), Galactosylceramides (chemistry), Glucosylceramides (analysis), Glucosylceramides (chemistry), Humans, Mice, Mice, Knockout, Molecular Structure, Parkinson Disease (diagnosis), Parkinson Disease (metabolism), Tandem Mass Spectrometry.
- MESH :
- chemical , analysis : Galactosylceramides, Glucosylceramides.
- chemical , chemistry : Galactosylceramides, Glucosylceramides.
- diagnosis : Parkinson Disease.
- metabolism : Brain, Parkinson Disease.
- Animals, Chromatography, High Pressure Liquid, Disease Models, Animal, Humans, Mice, Mice, Knockout, Molecular Structure, Tandem Mass Spectrometry.
Abstract
Previous studies demonstrated that Parkinson disease (PD) is associated with a decreased activity of the glucocerebrosidase (GCase) enzyme in brain tissues. The objective of this study was to determine if GCase deficiency is associated with the accumulation of its glucosylceramide (GluCer) substrate in PD brain tissues. An ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed, optimized, and validated for the multiplex analysis of GluCer isoforms (C18:0, C20:0, C22:0, C24:1, and C24:0) in brain tissue samples. These molecules were chromatographically separated from their isobaric galactosylceramide (GalCer) counterparts using normal phase chromatography. The analysis was performed by tandem mass spectrometry in the multiple reaction monitoring (MRM) acquisition mode. Limits of detection ranging from 0.4 to 1.1 nmol/g brain tissue were established for the different GluCer isoforms analyzed. For the first time, GluCer isoform levels were analyzed in temporal cortex brain tissue samples from 26 PD patients who were divided into three PD disease stages (IIa, III, and IV) according to the Unified Staging System for Lewy Body Disorders. These specimens were compared with brain tissue samples from 12 controls and 6 patients with Incidental Lewy Body Disease. No significant GluCer concentration differences were observed between the 5 sample groups. The GluCer isoform levels were also normalized with their matching GalCer isoforms. The normalized results showed a trend for GluCer levels which increased with PD severity. However, the differences observed between the groups were not significant, owing likely to the high standard deviations measured.
DOI: 10.1021/acs.analchem.5b04227
PubMed: 26735924
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000296
- to stream PubMed, to step Curation: 000296
- to stream PubMed, to step Checkpoint: 000296
- to stream Ncbi, to step Merge: 001E30
- to stream Ncbi, to step Curation: 001E30
- to stream Ncbi, to step Checkpoint: 001E30
- to stream Main, to step Merge: 000188
- to stream Main, to step Curation: 000188
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease.</title><author><name sortKey="Boutin, Michel" sort="Boutin, Michel" uniqKey="Boutin M" first="Michel" last="Boutin">Michel Boutin</name><affiliation><nlm:affiliation>Division of Medical Genetics, Department of Pediatrics, Centre de Recherche-CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke , 3001, 12th Avenue North, Sherbrooke, Quebec, Canada , J1H 5N4.</nlm:affiliation><wicri:noCountry code="subField">J1H 5N4</wicri:noCountry></affiliation></author><author><name sortKey="Sun, Ying" sort="Sun, Ying" uniqKey="Sun Y" first="Ying" last="Sun">Ying Sun</name><affiliation wicri:level="1"><nlm:affiliation>Division of Human Genetics, Cincinnati Children's Hospital Medical Center , R Building Room1401, 3333 Burnet Avenue, Cincinnati, Ohio 45229, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Human Genetics, Cincinnati Children's Hospital Medical Center , R Building Room1401, 3333 Burnet Avenue, Cincinnati, Ohio 45229</wicri:regionArea><wicri:noRegion>Ohio 45229</wicri:noRegion></affiliation></author><author><name sortKey="Shacka, John J" sort="Shacka, John J" uniqKey="Shacka J" first="John J" last="Shacka">John J. Shacka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Molecular and Cellular Pathology Division, University of Alabama at Birmingham , 1670 University Boulevard, VH G019H, Birmingham, Alabama 35294, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Molecular and Cellular Pathology Division, University of Alabama at Birmingham , 1670 University Boulevard, VH G019H, Birmingham, Alabama 35294</wicri:regionArea><wicri:noRegion>Alabama 35294</wicri:noRegion></affiliation></author><author><name sortKey="Auray Blais, Christiane" sort="Auray Blais, Christiane" uniqKey="Auray Blais C" first="Christiane" last="Auray-Blais">Christiane Auray-Blais</name><affiliation><nlm:affiliation>Division of Medical Genetics, Department of Pediatrics, Centre de Recherche-CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke , 3001, 12th Avenue North, Sherbrooke, Quebec, Canada , J1H 5N4.</nlm:affiliation><wicri:noCountry code="subField">J1H 5N4</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26735924</idno><idno type="pmid">26735924</idno><idno type="doi">10.1021/acs.analchem.5b04227</idno><idno type="wicri:Area/PubMed/Corpus">000296</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000296</idno><idno type="wicri:Area/PubMed/Curation">000296</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000296</idno><idno type="wicri:Area/PubMed/Checkpoint">000296</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000296</idno><idno type="wicri:Area/Ncbi/Merge">001E30</idno><idno type="wicri:Area/Ncbi/Curation">001E30</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E30</idno><idno type="wicri:Area/Main/Merge">000188</idno><idno type="wicri:Area/Main/Curation">000188</idno><idno type="wicri:Area/Main/Exploration">000188</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease.</title><author><name sortKey="Boutin, Michel" sort="Boutin, Michel" uniqKey="Boutin M" first="Michel" last="Boutin">Michel Boutin</name><affiliation><nlm:affiliation>Division of Medical Genetics, Department of Pediatrics, Centre de Recherche-CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke , 3001, 12th Avenue North, Sherbrooke, Quebec, Canada , J1H 5N4.</nlm:affiliation><wicri:noCountry code="subField">J1H 5N4</wicri:noCountry></affiliation></author><author><name sortKey="Sun, Ying" sort="Sun, Ying" uniqKey="Sun Y" first="Ying" last="Sun">Ying Sun</name><affiliation wicri:level="1"><nlm:affiliation>Division of Human Genetics, Cincinnati Children's Hospital Medical Center , R Building Room1401, 3333 Burnet Avenue, Cincinnati, Ohio 45229, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Human Genetics, Cincinnati Children's Hospital Medical Center , R Building Room1401, 3333 Burnet Avenue, Cincinnati, Ohio 45229</wicri:regionArea><wicri:noRegion>Ohio 45229</wicri:noRegion></affiliation></author><author><name sortKey="Shacka, John J" sort="Shacka, John J" uniqKey="Shacka J" first="John J" last="Shacka">John J. Shacka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Molecular and Cellular Pathology Division, University of Alabama at Birmingham , 1670 University Boulevard, VH G019H, Birmingham, Alabama 35294, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Molecular and Cellular Pathology Division, University of Alabama at Birmingham , 1670 University Boulevard, VH G019H, Birmingham, Alabama 35294</wicri:regionArea><wicri:noRegion>Alabama 35294</wicri:noRegion></affiliation></author><author><name sortKey="Auray Blais, Christiane" sort="Auray Blais, Christiane" uniqKey="Auray Blais C" first="Christiane" last="Auray-Blais">Christiane Auray-Blais</name><affiliation><nlm:affiliation>Division of Medical Genetics, Department of Pediatrics, Centre de Recherche-CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke , 3001, 12th Avenue North, Sherbrooke, Quebec, Canada , J1H 5N4.</nlm:affiliation><wicri:noCountry code="subField">J1H 5N4</wicri:noCountry></affiliation></author></analytic><series><title level="j">Analytical chemistry</title><idno type="eISSN">1520-6882</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Brain (metabolism)</term><term>Chromatography, High Pressure Liquid</term><term>Disease Models, Animal</term><term>Galactosylceramides (analysis)</term><term>Galactosylceramides (chemistry)</term><term>Glucosylceramides (analysis)</term><term>Glucosylceramides (chemistry)</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Molecular Structure</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (metabolism)</term><term>Tandem Mass Spectrometry</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Galactosylceramides</term><term>Glucosylceramides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Galactosylceramides</term><term>Glucosylceramides</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chromatography, High Pressure Liquid</term><term>Disease Models, Animal</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Molecular Structure</term><term>Tandem Mass Spectrometry</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous studies demonstrated that Parkinson disease (PD) is associated with a decreased activity of the glucocerebrosidase (GCase) enzyme in brain tissues. The objective of this study was to determine if GCase deficiency is associated with the accumulation of its glucosylceramide (GluCer) substrate in PD brain tissues. An ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed, optimized, and validated for the multiplex analysis of GluCer isoforms (C18:0, C20:0, C22:0, C24:1, and C24:0) in brain tissue samples. These molecules were chromatographically separated from their isobaric galactosylceramide (GalCer) counterparts using normal phase chromatography. The analysis was performed by tandem mass spectrometry in the multiple reaction monitoring (MRM) acquisition mode. Limits of detection ranging from 0.4 to 1.1 nmol/g brain tissue were established for the different GluCer isoforms analyzed. For the first time, GluCer isoform levels were analyzed in temporal cortex brain tissue samples from 26 PD patients who were divided into three PD disease stages (IIa, III, and IV) according to the Unified Staging System for Lewy Body Disorders. These specimens were compared with brain tissue samples from 12 controls and 6 patients with Incidental Lewy Body Disease. No significant GluCer concentration differences were observed between the 5 sample groups. The GluCer isoform levels were also normalized with their matching GalCer isoforms. The normalized results showed a trend for GluCer levels which increased with PD severity. However, the differences observed between the groups were not significant, owing likely to the high standard deviations measured.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Auray Blais, Christiane" sort="Auray Blais, Christiane" uniqKey="Auray Blais C" first="Christiane" last="Auray-Blais">Christiane Auray-Blais</name><name sortKey="Boutin, Michel" sort="Boutin, Michel" uniqKey="Boutin M" first="Michel" last="Boutin">Michel Boutin</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Sun, Ying" sort="Sun, Ying" uniqKey="Sun Y" first="Ying" last="Sun">Ying Sun</name></noRegion><name sortKey="Shacka, John J" sort="Shacka, John J" uniqKey="Shacka J" first="John J" last="Shacka">John J. Shacka</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000188 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000188 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26735924
|texte= Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26735924" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |